RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $235 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $235. This reaffirmation of the stock's potential could influence its market performance.
February 16, 2024 | 4:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital's reaffirmation of an Outperform rating and a $235 price target on Alnylam Pharmaceuticals could positively influence its stock in the short term.
Analyst ratings and price targets are significant indicators for investors, often influencing stock prices. The reiteration of a positive outlook by a reputable analyst like Luca Issi from RBC Capital, especially with a high price target of $235, suggests a strong conviction in the company's future performance. This can lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100